1. bookVolume 29 (2021): Issue 1 (January 2021)
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo

FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients

Published Online: 29 Jan 2021
Page range: 33 - 41
Received: 01 Oct 2020
Accepted: 11 Dec 2020
Journal Details
License
Format
Journal
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Copyright
© 2020 Sciendo
Abstract

FMS-like tyrosine kinase 3 gene internal tandem (FLT3-ITD) mutations represent one of the most frequent genetic lesions in acute myeloid leukemia (AML) and imparts a negative prognostic. For an optimal patient management, current clinical guidelines recommend the evaluation of the allelic ratio (AR), expressed as the DNA FLT3-ITD/WT mutational burden. We sought to evaluate the differences between the AR and FLT3-ITD/WT mRNA ratio (RR) and their respective impact on the biological characteristics of AML patients. A total of 32 DNA and mRNA samples from AML patients with FLT3-ITD were evaluated. There was a good correlation between the AR and RR (Spearman’s rho= 0.652, P <0.001). None of the biological characteristics were influenced by the RR values, whereas patients with high AR values (≥0.5) had higher WBC counts (Mann-Whitney, P= 0.01), LDH levels (Mann-Whitney, P= 0.037), and circulating blasts levels (Mann-Whitney, P= 0.023) than patients with low AR values (<0.5). Also, there was a good correlation between AR values and WBC count (Spearman’s correlation, P= 0.001), and LDH levels (Spearman’s correlation, P= 0.007). In our study population the AR, but not the RR, influenced the biological characteristic of patients suggesting a dose-independent effect of FLT3-ITD mutations.

Keywords

1. Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia [Internet]. 2019;33(2):299–312. DOI: 10.1038/s41375-018-0357-9Search in Google Scholar

2. Levis M. FLT3 mutations in acute myeloid leukemia: what is the best approach in 2013? Hematology Am Soc Hematol Educ Program [Internet]. 2013;2013:220–6. DOI: 10.1182/asheducation-2013.1.220Search in Google Scholar

3. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood [Internet]. 2017 Jan 26;129(4):424–47. DOI: 10.1182/blood-2016-08-733196Search in Google Scholar

4. Gale RE, Green C, Allen C, Mead AJ, Burnett AK, Hills RK, et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood. 2008;111(5):2776–84. DOI: 10.1182/blood-2007-08-109090Search in Google Scholar

5. Pratcorona M, Brunet S, Nomdedeu J, Ribera JM, Tormo M, Duarte R, et al. Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy. Blood [Internet]. 2013 Apr 4;121(14):2734–8. DOI: 10.1182/blood-2012-06-431122Search in Google Scholar

6. Schlenk RF, Kayser S, Bullinger L, Kobbe G, Casper J, Ringhoffer M, et al. Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation. Blood [Internet]. 2014 Nov 27;124(23):3441–9. DOI: 10.1182/blood-2014-05-578070Search in Google Scholar

7. Linch DC, Hills RK, Burnett AK, Khwaja A, Gale RE. Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia. Blood [Internet]. 2014 Jul 10;124(2):273–6. DOI: 10.1182/blood-2014-02-554667Search in Google Scholar

8. Boddu PC, Kadia TM, Garcia‐Manero G, Cortes J, Alfayez M, Borthakur G, et al. Validation of the 2017 European LeukemiaNet classification for acute myeloid leukemia with NPM1 and FLT3 internal tandem duplication genotypes. Cancer [Internet]. 2019 Apr 6;125(7):1091–100. DOI: 10.1002/cncr.31885Search in Google Scholar

9. Sakaguchi M, Yamaguchi H, Najima Y, Usuki K, Ueki T, Oh I, et al. Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Adv [Internet]. 2018 Oct 23;2(20):2744–54. DOI: 10.1182/bloodadvances.2018020305Search in Google Scholar

10. Harada Y, Nagata Y, Kihara R, Ishikawa Y, Asou N, Ohtake S, et al. Prognostic analysis according to the 2017 ELN risk stratification by genetics in adult acute myeloid leukemia patients treated in the Japan Adult Leukemia Study Group (JALSG) AML201 study. Leuk Res [Internet]. 2018 Mar 1 [cited 2019 Jul 2];66:20–7.Search in Google Scholar

11. Huang Y, Hu J, Lu T, Luo Y, Shi J, Wu W, et al. Acute myeloid leukemia patient with FLT3-ITD and NPM1 double mutation should undergo allogeneic hematopoietic stem cell transplantation in CR1 for better prognosis. Cancer Manag Res [Internet]. 2019 May;Volume 11:4129–42. DOI: 10.2147/CMAR.S194523Search in Google Scholar

12. Schneider F, Hoster E, Unterhalt M, Schneider S, Dufour A, Benthaus T, et al. The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype. Blood [Internet]. 2012 May 10;119(19):4383–6. DOI: 10.1182/blood-2010-12-327072Search in Google Scholar

13. Cucchi DGJ, Denys B, Kaspers GJL, Janssen JJWM, Ossenkoppele GJ, de Haas V, et al. RNA-based FLT3 -ITD allelic ratio is associated with outcome and ex vivo response to FLT3 inhibitors in pediatric AML. Blood [Internet]. 2018 May 31;131(22):2485–9. DOI: 10.1182/blood-2017-12-819508Search in Google Scholar

14. Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93(9):3074–80.Search in Google Scholar

15. Kottaridis PD, Gale RE, Frew ME, Harrison G, Langabeer SE, Belton AA, et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic patients from the United Kingdom Medical Research Council AML 10 and 12.pdf. Blood. 2001;98(6):1752–60. DOI: 10.1182/blood.V98.6.1752Search in Google Scholar

16. Thiede C, Steudel C, Mohr B, Schaich M, Schaekel U, Bornhaeuser M, et al. Analysis of FLT3-activating mutations in 713 patients with acute myelogenous leukemia (AML): High prevalence in FAB-subtype M5 and identification of subgroups with poor prognosis. Blood. 2001;98(11, Part 1):2994.Search in Google Scholar

17. Reiter K, Polzer H, Krupka C, Maiser A, Vick B, Rothenberg-Thurley M, et al. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia. Leukemia [Internet]. 2018 Feb 14;32(2):313–22. DOI: 10.1038/leu.2017.257Search in Google Scholar

Plan your remote conference with Sciendo